Photo Gallery



News & Updation

  • JUNE 2018 Issue has been successfully launched on 1 June 2018

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.



Halla M. Ragab*, Fawzy A. Attaby, Nabila Abd El Maksoud, Wael Mohamed Aref, Mona A. Amin, Heba K. Abdelhakim and Wafaa Abd Elaziz*


Early outcome prediction after hepatitis C viral infections has a great interest. This study aims to evaluate kallistatin in the prediction of liver fibrosis in chronic hepatitis C Egyptian patients. This study included 62 patients with chronic HCV infection (30 patients suffering from early liver fibrosis, 16 with advanced liver fibrosis, 16 with HCC) and 14 healthy subjects. Serum liver function tests were determined by colorimetric methods, HBsAg, HCVAb, AFP, CRP and kallistatin were investigated by ELISA, HCV-RNA and the expression of SERPINA4 gene were determined by qRT-PCR assay, abdominal ultrasound and ultrasonic-guided liver biopsy were done to determine the stage of fibrosis. Serum kallistatin level was significantly lower in patients with chronic liver disease (CLD) than healthy subjects at the gene expression and protein levels (P=0.003 & 0.001, respectively). Also, there was a significant difference in kallistatin concentration in early and advanced fibrosis, (p=0.044). Serum kallistatin had greater sensitivity and NPV values than did AST/ALT ratio (AAR) and AST/platelet ratio index (APRI) in patients with CLD compared with healthy subjects with sensitivity 95.1%, specificity 50%, PPV 89.2%, and NPV 70%. Moreover, Kallistatin could significantly distinguish patients at early stage of liver fibrosis from healthy subjects with sensitivity 96.7% and specificity 50%. Compared with single detection, combined measurement of the AAR, APRI and kallistatin markers showed 90% sensitivity and 78.6% specificity, 90% PPV and 78.6% NPV. These data support that kallistatin may be an efficient biomarker in early detection of fibrosis. Also, it suggested that combination of kallistatin with AAR and APRI could improve the sensitivity and specificity for the diagnosis of CLD and this can be used as a practical method for clinical diagnosis for the early stage of liver fibrosis.

Keywords: Chronic liver disease, Kallistatin, SERPINA4, qRT-PCR, ELISA.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More